Clinical trial NCT00237354: PV-10 Chemoablation of Recurrent Breast Carcinoma
Official title: A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Breast Cancer
Keywords: Recurrent soft tissue breast carcinoma
Lead sponsor: Provectus Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-10-12
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of recurrent breast carcinoma. This study will also include a preliminary assessment of response of injected lesions by histologic assessment upon lesion excision at 1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.

Detailed description: This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Eligibility criteria: Inclusion Criteria:

* Biopsy confirmed recurrent soft tissue breast carcinoma
* At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter
* Performance Status: Karnofsky 70-100% or ECOG 0-2
* Life Expectancy: At least 6 months
* Hematopoietic:

  * White blood cell count (WBC) at least 3000/mm3
  * Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
  * Hemoglobin at least 10 g/dL
  * Platelet count at least 100,000/mm3
* Coagulopathy: International Normalized Ratio (INR) at least 1.5.
* Renal Function: Creatinine = 0.05-0.11 mmol/L
* Hepatic Function:

  * Bilirubin = 3-21 umol/L
  * AST/ALT ≤ 3 times the upper limit of normal (ULN)
* Cardiovascular Function: No major cardiovascular disease
* Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
* Immunological Function: Adequate immune system function in the opinion of the investigator

Exclusion Criteria:

* Radiation therapy to study lesions within 4 weeks
* Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin)
* Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
* Investigational agents within 4 weeks (or 5 half-lives)
* Anti-tumor vaccine therapy within 12 weeks
* Concurrent illness:

  * Severe diabetes or extremity complications due to diabetes
  * Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
  * Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
* Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating
* Known or suspected brain metastases or spinal cord compression.

Primary outcomes:
measure: Systemic and locoregional adverse experience
timeFrame: 5-7 weeks post dosing (4 weeks post excision)
Secondary outcomes:
measure: Histopathologic response of PV-10 injected lesions
timeFrame: 7-21 days post dosing
measure: Wound healing of PV-10 injected lesions
timeFrame: 5-7 weeks post dosing (4 weeks post excision)
Other outcomes:
Locations:
city: Christchurch
country: New Zealand
facility: Canterbury BreastCare
Study officials:
affiliation: Provectus Pharmaceuticals, Inc.
name: Eric Wachter, Ph.D.
role: STUDY_DIRECTOR
affiliation: Oncology Service, Christchurch Hospital
name: Chris Wynne, M.D.
role: PRINCIPAL_INVESTIGATOR
References: